You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
CARDIOLIPIN IGA ANTIBODY |
||
Geisinger Epic Procedure Code: LAB1942
Geisinger Epic ID: 26876
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum (preferred) or sodium citrate plasma | |
Preferred collection container: |
||
Alternate Collection Container: |
6 mL red-top (plain, non-serum separator) tube
2.7 mL blue-top (3.2% sodium citrate) tube
|
|
Specimen required: |
0.5 mL serum (preferred) or sodium citrate plasma; minimum 0.2 mL. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow serum to clot. Centrifuge and submit 0.5 mL serum or plasma. | |
Transport temperature: |
Refrigerated (preferred). Room temperature (stable 8 hours) and frozen specimens also acceptable. | |
Specimen stability: |
Room temperature: 8 hours. 2-8°C: 48 hours. Frozen: 6 months. | |
Rejection criteria: |
Specimen stability exceeded; specimen grossly hemolyzed. | |
TEST DETAILS |
||
Reference interval: |
Negative <14 APL-U/mL | |
Interpretation guide: |
Negative <14 APL-U/mL Equivocal 14-20 APL-U/mL Positive >20 APL-U/mL |
|
Additional information: |
Sodium citrate plasma has been validated for use with this assay for those patients ordered for Anti-Lupus Coagulation panels (LUPACP or LUPACC) without an available serum sample. | |
CPT code(s): |
86147 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Cardiolipin IgA antibody. | |
Methodology: |
Enzyme Immunoassay (EIA) |
|
Synonyms: |
CARDA, Cardiolipin antibody IgA Antiphospholipid IgA antibody ACA IgA antibody, ACL IgA antibody Anticardiolipin IgA AB
|
|
Clinical significance: |
The presence of cardiolipin antibodies when used in conjunction with clinical findings and other laboratory tests can aid in assessing the risk of thromboembolic disease in patients with systemic lupus erythematosus (SLE) or primary anti-phospholipid syndrome (APS). | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu PhD, DABCC, FADLM | |
| Review Date: | 12/13/2022 | |